Phase I study of combination therapy with peptide vaccine and anti-cancer drug for colorectal cancer has been performed in our hospital. The purpose of this study was to evaluate the safety and immune response of different dose of RNF43-721 emulsified with Montanide ISA 51 in combination with S-1/CPT-11 chemotherapy. The study design was a dose escalation of peptide (0.5, 1.0, 3.0 mg) with three patients' cohort. Nine patients were enrolled. All patients were treated with peptide subcutaneously every week and two courses with S-1/CPT-11 chemotherapy. Vaccinations were well tolerated without any major adverse events. Immunological reactions are not analyzed yet. We herein report a case who has been evaluated to be long SD with this intervention for para-aortic LN metastasis from sigmoid colon cancer.

Download full-text PDF

Source

Publication Analysis

Top Keywords

study combination
8
combination therapy
8
therapy peptide
8
peptide vaccine
8
vaccine anti-cancer
8
anti-cancer drug
8
drug colorectal
8
s-1/cpt-11 chemotherapy
8
[phase study
4
peptide
4

Similar Publications

Unlabelled: Patients with breast cancer (BC) are at high risk of cardiotoxicity (CT) due to combination of anticancer treatment.Cardio-vascular (СV) complications lead to the delay or discontinuation of anticancer therapy, which significantlyworsens the prognosis. Anthracyclines (AC) are the main drugs included in most anticancer treatment regimens.

View Article and Find Full Text PDF

Optimizing Catheter Verification: An Understandable AI Model for Efficient Assessment of Central Venous Catheter Placement in Chest Radiography.

Invest Radiol

October 2024

From the Department of Radiology and Nuclear Medicine, UKSH Lübeck, Lübeck, Germany (J.S., M.M., L.B., Y.E., J.B., M.M.S.); Institute of Medical Informatics, University of Lübeck, Lübeck, Germany (L.H., M.P.H.); Philips Research Hamburg, Hamburg, Germany (A.S., H.S.); and Institute of Interventional Radiology, UKSH Lübeck, Lübeck, Germany (M.M.S.).

Purpose: Accurate detection of central venous catheter (CVC) misplacement is crucial for patient safety and effective treatment. Existing artificial intelligence (AI) often grapple with the limitations of label inaccuracies and output interpretations that lack clinician-friendly comprehensibility. This study aims to introduce an approach that employs segmentation of support material and anatomy to enhance the precision and comprehensibility of CVC misplacement detection.

View Article and Find Full Text PDF

Elastography-based AI model can predict axillary status after neoadjuvant chemotherapy in breast cancer with nodal involvement: A prospective, multicenter, diagnostic study.

Int J Surg

October 2024

Department of Medical Ultrasound, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.

Objective: To develop a model for accurate prediction of axillary lymph node (LN) status after neoadjuvant chemotherapy (NAC) in breast cancer patients with nodal involvement.

Methods: Between October 2018 and February 2024, 671 breast cancer patients with biopsy-proven LN metastasis who received NAC followed by axillary LN dissection were enrolled in this prospective, multicenter study. Preoperative ultrasound (US) images, including B-mode ultrasound (BUS) and shear wave elastography (SWE), were obtained.

View Article and Find Full Text PDF

Objective: Inflammatory characteristics in pericoronary adipose tissue (PCAT) may enhance the diagnostic capability of radiomics techniques for identifying vulnerable plaques. This study aimed to evaluate the incremental value of PCAT radiomics scores in identifying vulnerable plaques defined by intravascular ultrasound imaging (IVUS).

Methods: In this retrospective study, a PCAT radiomics model was established and validated using IVUS as the reference standard.

View Article and Find Full Text PDF

Purpose Of Review: To review the recent updates in the management of cervical cancer across all stages of the disease.

Recent Findings: After decades of minor advances, the landscape in cervical cancer is now rapidly changing. Recent studies have reported across the cervical cancer spectrum and on different therapeutic modalities.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!